Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXNYSE:LHNASDAQ:NTRANYSE:NVTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$173.54-1.3%$168.88$134.05▼$178.87$19.37B0.78962,228 shs536,249 shsLHLaboratory Co. of America$228.27-0.1%$235.65$191.97▼$258.59$19.09B0.99637,620 shs465,359 shsNTRANatera$153.67-0.5%$148.26$87.20▼$183.00$20.79B1.81.38 million shs327,581 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.22%+7.43%+6.30%+13.23%+27.90%LHLaboratory Co. of America+1.92%+5.20%-2.15%-7.21%+9.91%NTRANatera+3.98%+4.32%-0.06%-7.83%+68.83%NVTAInvitae0.00%0.00%0.00%0.00%-70.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.519 of 5 stars2.32.04.24.73.92.51.3LHLaboratory Co. of America4.7663 of 5 stars3.44.02.54.23.42.51.3NTRANatera2.9789 of 5 stars3.53.00.00.03.42.50.6NVTAInvitaeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.69Moderate Buy$183.735.87% UpsideLHLaboratory Co. of America 2.87Moderate Buy$268.7717.74% UpsideNTRANatera 3.00Buy$175.7614.38% UpsideNVTAInvitae 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVTA, NTRA, DGX, and LH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DGXQuest DiagnosticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$182.00 ➝ $190.004/23/2025DGXQuest DiagnosticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetIn-Line ➝ In-Line$175.00 ➝ $180.004/23/2025DGXQuest DiagnosticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$175.00 ➝ $185.004/23/2025DGXQuest DiagnosticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$191.00 ➝ $194.004/11/2025LHLaboratory Co. of AmericaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$285.00 ➝ $274.004/10/2025LHLaboratory Co. of AmericaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $240.004/10/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $160.004/9/2025DGXQuest DiagnosticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$178.00 ➝ $189.004/2/2025DGXQuest DiagnosticsRedburn PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$195.004/2/2025DGXQuest DiagnosticsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$195.004/2/2025LHLaboratory Co. of AmericaRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$276.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$10.16B1.91$13.54 per share12.82$61.04 per share2.84LHLaboratory Co. of America$13.01B1.47$20.58 per share11.09$96.27 per share2.37NTRANatera$1.70B12.24N/AN/A$6.37 per share24.12NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.9122.5716.542.168.80%15.07%6.72%N/ALHLaboratory Co. of America$746M$8.8225.8713.011.715.73%15.29%7.01%4/29/2025 (Estimated)NTRANatera-$434.80M-$1.53N/AN/AN/A-14.01%-26.23%-14.27%5/8/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ALatest NVTA, NTRA, DGX, and LH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59N/AN/AN/A$446.68 millionN/A4/29/2025Q1 2025LHLaboratory Co. of America$3.75N/AN/AN/A$3.41 billionN/A4/22/2025Q1 2025DGXQuest Diagnostics$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billion2/27/2025Q4 2024NTRANatera-$0.42-$0.41+$0.01-$0.41$447.91 million$476.10 million2/6/2025Q4 2024LHLaboratory Co. of America$3.40$3.45+$0.05$1.70$3.31 billionN/A1/30/2025Q4 2024DGXQuest Diagnostics$2.19$2.23+$0.04$1.95$2.58 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.84%+6.94%40.46%14 YearsLHLaboratory Co. of America$2.881.26%N/A32.65%N/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ALatest NVTA, NTRA, DGX, and LH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/10/2025LHLaboratory Co. of Americaquarterly$0.721.25%5/29/20256/11/20251/30/2025DGXQuest Diagnosticsquarterly$0.802.06%4/7/20254/7/20254/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.821.101.02LHLaboratory Co. of America0.671.441.30NTRANatera0.334.394.23NVTAInvitaeN/A2.392.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%LHLaboratory Co. of America95.94%NTRANatera99.90%NVTAInvitae61.28%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%LHLaboratory Co. of America0.84%NTRANatera7.60%NVTAInvitae0.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics49,000111.61 million110.73 millionOptionableLHLaboratory Co. of America75,50083.67 million82.93 millionOptionableNTRANatera3,020135.19 million121.99 millionOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableNVTA, NTRA, DGX, and LH HeadlinesRecent News About These CompaniesInvitae Corp (OTC:NVTA) Stock, Insider Trading ActivityOctober 3, 2024 | benzinga.comLabcorp completes acquisition of select assets of InvitaeAugust 6, 2024 | pharmabiz.comInvitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy PatientsJuly 22, 2024 | finance.yahoo.comKirkland Cleared to Represent Invitae After Conflict ObjectionsMay 7, 2024 | news.bloomberglaw.comInvitae's $239 million sale to Labcorp approved by Bankruptcy CourtMay 7, 2024 | bizjournals.comLabcorp Makes Another Acquisition, Plucking Invitae Assets From Bankruptcy AuctionApril 29, 2024 | medcitynews.comLabCorp On the Verge of Acquiring Invitae’s AssetsApril 29, 2024 | mddionline.comLabcorp to acquire Invitae in strategic dealApril 28, 2024 | msn.comKirkland Defends Invitae Representation Amid Conflict ClaimsApril 26, 2024 | news.bloomberglaw.comLabcorp picks up Invitae portfolio for $239M in bankruptcy saleApril 26, 2024 | fiercebiotech.comLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | uk.investing.comLabcorp wins $239M bid for bankrupt InvitaeApril 26, 2024 | bizjournals.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealApril 25, 2024 | msn.comInvitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of BusinessApril 25, 2024 | finanznachrichten.deLabcorp Acquiring Invitae Assets for $239M, Posts 5 Percent Rise in Q1 RevenuesApril 25, 2024 | 360dx.comLabcorp to Buy Assets of Bankrupt Invitae for $239MApril 25, 2024 | marketwatch.comClinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnApril 24, 2024 | reuters.comInvitae Enters into Agreement with Labcorp for Sale of BusinessApril 24, 2024 | finance.yahoo.comLabcorp Announces Winning Bid for Select Assets of InvitaeApril 24, 2024 | prnewswire.comInvitae Publishes its Environmental, Social and Governance (ESG) ReportApril 22, 2024 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNATO Deal Sparks 4% Jump in Palantir Stock—What’s Next?By Chris Markoch | April 15, 2025View NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next?Is Archer Aviation’s Stock Price Dip a Gift?By Jeffrey Neal Johnson | April 11, 2025View Is Archer Aviation’s Stock Price Dip a Gift?Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s FutureBy Ryan Hasson | April 3, 2025View Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s FutureOracle Stock: Resilient, Undervalued, and Ready to ReboundBy Thomas Hughes | April 14, 2025View Oracle Stock: Resilient, Undervalued, and Ready to ReboundRocket Lab's Growth Potential Gains Altitude on Defense NewsBy Ryan Hasson | April 17, 2025View Rocket Lab's Growth Potential Gains Altitude on Defense NewsNVTA, NTRA, DGX, and LH Company DescriptionsQuest Diagnostics NYSE:DGX$173.54 -2.33 (-1.32%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Laboratory Co. of America NYSE:LH$228.26 -0.32 (-0.14%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$153.66 -0.82 (-0.53%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
